Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific administrative event: a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan, which resulted in an increase in the notional allocation of American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: The notional allocation increase occurred on September 28, 2012.
- Transaction Price: The ADS price was $46.24 per share.
- Involved Parties: Dr. M M Slaoui (Director/PDMR) had no change in allocation; Dr. K Slaoui (Connected Person) received an allocation of 4 ADSs.
- Plan Details: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK ADSs.